ATTR Trial’s Safety Freeze; Heart Failure After Twins; Sotatercept Approval Expands

(MedPage Today) — The phase III trial studying CRISPR gene editing therapy for transthyretin amyloidosis (ATTR) was paused for safety due to an alarming case of poor liver function in one patient, Intellia Therapeutics said.
A placebo-controlled…